Aktis Oncology prices upsized US IPO at $18 per share
Cancer drug developer Aktis Oncology said on Thursday it priced its upsized U.S. initial public offering at $18 per share, raising about $318 million. Aktis is targeting a valuation of…
Aktis Oncology Files for US IPO as Biotech Listings Rebound
Aktis Oncology filed for an initial public offering in the United States on Friday, as stock market listings from the biotech industry rebound after a slowdown. After a months-long drought,…